• 1
    Almahameed A, Pinto DS. Pernio (chilblains). Curr Treat Options Cardiovasc Med 2008; 10:128135.
  • 2
    Boada A, Bielsa I, Fernández-Figueras MT, Ferrándiz C. Perniosis: clinical and histopathological analysis. Am J Dermatopathol 2010; 32:1923.
  • 3
    Prakash S, Weisman MH. Idiopathic chilblains. Am J Med 2009; 122:11521155.
  • 4
    Price RD, Murdoch DR. Perniosis (chilblains) of the thigh: report of five cases, including four following river crossings. High Alt Med Biol 2001; 2:535538.
  • 5
    Viguier M, Pinquier L, Cavelier-Balloy B, de la Salmoniere P. Clinical and histopathologic features and immunologic variables in patients with severe chilblains. A study of the relationship to lupus erythematosus. Medicine (Baltimore) 2001; 80:180183.
  • 6
    Hirschl M, Hirschl K, Lenz M, et al. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum 2006; 54:19741981.
  • 7
    Chikura B, Moore T, Manning J, et al. Thumb involvement in Raynaud's phenomenon as an indicator of underlying connective tissue disease. J Rheumatol 2010; 37:783786.
  • 8
    Yang X, Perez OA, English JC III. Successful treatment of perniosis with hydroxychloroquine. J Drugs Dermatol 2010; 9:12421246.
  • 9
    Patra AK, Das AL, Ramadasan P. Diltiazem vs. nifedipine in chilblains: a clinical trial. Indian J Dermatol Venereol Leprol 2003; 69:209211.
  • 10
    Vinjar B, Stewart M. Oral vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev 2008.